Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I pharmacokinetics study of ifenprodil in healthy Chinese male subjects
ChiCTR-TNC-10000910Phase 4Completed
- Sponsor
- Southwest Health System
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ifenprodil in stroke, traumatic brain injury (TBI), Dementia and 3 more (2 arms), sponsored by Southwest Health System. Primary endpoint: Plasma concentration of ifenprodil after single dose and at steady state. Started May 2008; status: completed.
02
Drugs
ifenprodil
03
Conditions
stroketraumatic brain injury (TBI)Dementiaacute sensorineural hearing losscerebral vasospasm
Beyond the preview
Go deeper on ChiCTR-TNC-10000910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNC-10000910.